Sustained Or Differential Release Type Patents (Class 514/964)
  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 8889190
    Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: November 18, 2014
    Assignee: Upsher-Smith Laboratories, Inc.
    Inventors: Sarah Michelle Betterman, Jaidev Srinivas Tantry, Laura Marie Patrick
  • Patent number: 8865021
    Abstract: The present invention relates to compositions containing at least one cationic peptide active agent, at least one neutral structure forming amphiphile, at least one anionic structure forming amphiphile and optionally at least one solvent wherein the composition is in the form of a non-lamellar phase structure and/or forms a nonlamellar phase structure on exposure to body fluids. The invention also relates to methods for protecting peptides from enzymic degredation in vivo and to compositions in which the peptide active agent is so protected.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: October 21, 2014
    Assignee: Camurus AB
    Inventors: Fredrik Joabsson, Fredrik Tiberg
  • Patent number: 8770201
    Abstract: Condoms having an elastomeric layer and coating containing an anhydrous warming lubricant and at least one or more ingredients dispersed therein, the coating being disposed on one or both surfaces are provided. The ingredients disposed on the elastomeric layer can be solid particles or encapsulated ingredients that are insoluble in the anhydrous warming lubricant and soluble in water. Methods of producing and using these condoms are also provided.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: July 8, 2014
    Assignee: GlycoBioSciences Inc.
    Inventors: Michael S. Zedalis, Beng Sim Chuah, David M. Lucas, Angela M. Shiokawa, Jose R. Siqueira, Dave Narasimhan
  • Patent number: 8652527
    Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: February 18, 2014
    Assignee: Upsher-Smith Laboratories, Inc
    Inventors: Sarah Michelle Betterman, Jaidev Srinvas Tantry, Laura Marie Patrick
  • Patent number: 8623409
    Abstract: An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: January 7, 2014
    Assignee: Tris Pharma Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 8523569
    Abstract: The present invention relates to a method of delivering local anesthetic after dental extraction surgery. The present invention relates to packing the tooth socket with a tinned release local anesthetic which is coordinated with an initial local anesthetic and which lasts up to 5 days. The socket can be surgically sealed or the implant can act as the sealing means.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: September 3, 2013
    Inventor: Khashayar Kevin Neshat
  • Patent number: 8481019
    Abstract: The present invention relates to novel particles comprising polyelectrolyte polymers which are transporters of active principle (AP), in particular protein and peptide active principle, and to novel modified-release pharmaceutical formulations comprising said AP microparticles. These novel particles loaded with AP release the AP over a prolonged period of time of several days, or even several weeks.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: July 9, 2013
    Assignee: Flamel Technologies
    Inventors: Cecile Bonnet-Gonnet, Frédéric Checot, You-Ping Chan, Olivier Breyne
  • Patent number: 8435953
    Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: May 7, 2013
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventor: Yasuhiko Tabata
  • Patent number: 8426472
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: April 23, 2013
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 8383151
    Abstract: A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: February 26, 2013
    Assignee: Lupin Limited
    Inventors: Harshal Anil Jahagirdar, Rajesh Kulkarni, Shirishkumar Kulkarni
  • Patent number: 8192755
    Abstract: An improved stable pharmaceutical composition for controlled release of an active ingredient comprises a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters as active ingredient, a calcium salt and a mixture of hydrophilic polymers selected from the group consisting of at least one sodium alginate and one xanthan gum and with or without hydroxypropyl methylcellulose, said composition optionally containing probenecid. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers and water soluble and/or water dispersible diluents are such that the therapeutically effective active ingredient is released at a rate suitable for once or twice daily administration of the pharmaceutical composition.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: June 5, 2012
    Assignee: Lupin Limited
    Inventors: Himadri Sen, Rajesh Suresh Kshirsagar, Shailesh Suresh Bhamare
  • Patent number: 8084059
    Abstract: The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: December 27, 2011
    Assignee: ALZA Corporation
    Inventors: David Emil Edgren, Gurdish Kaur Bhatti, Zahedeh Hatamkhani, Patrick S. L. Wong
  • Patent number: 8030355
    Abstract: A tamsulosin controlled release tablet is formed using a water-swellable matrix-forming composition as a release controlling mechanism. The matrix forming composition comprises (i) a pH-sensitive swellable hydrophilic polymer, which is a cross-linked polyacrylic acid polymer, and (ii) a pH-insensitive swellable hydrophilic polymer. The tablet optionally contains a water insoluble binder as well.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: October 4, 2011
    Assignee: Synthon BV
    Inventors: Korinde Annemarie Jansen, Farid Abedin Dorkoosh
  • Patent number: 7989003
    Abstract: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: August 2, 2011
    Assignee: Zicam, LLC
    Inventors: Charles Hensley, Robert Steven Davidson
  • Patent number: 7858656
    Abstract: A controlled release melatonin tablet having a slow release nucleus of melatonin, hydroxypropyl methylcellulose, a lubricant, a volume excipient and a glidant, wherein 95% of the melatonin is released within 5 hours in an oscillating tray containing gastric/intestinal juice at 37° C. and a fast release cortex coating on said nucleus of melatonin, hydroxypropyl methylcellulose and a volume excipient, wherein at least 95% of the melatonin is released within 10 minutes in an oscillating tray containing gastric/intestinal juice at 37° C.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: December 28, 2010
    Assignee: Ambros Pharma S.R.L.
    Inventor: Bojidar M. Stankov
  • Patent number: 7842377
    Abstract: A composition includes a plurality of particles. At least some of the plurality of particles include cross-linked polyvinyl alcohol and have a diameter of about 500 microns or less. The particles have a first average pore size in an interior region, and a second average pore size at a surface region. The first average pore size being greater than the second average pore size. The composition also includes a carrier fluid. The plurality of particles being in the carrier fluid.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: November 30, 2010
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Janel Lanphere, Ernest J. St. Pierre, Greg Kapoglis, Thomas V. Casey, II
  • Patent number: 7780986
    Abstract: The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: August 24, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Venkata-Rangarao Kanikanti, Roland Rupp, Wolfgang Weber, Peter Deuringer, Jan-Olav Henck, Heino Stab, Takaaki Nishioka, Yoshifumi Katakawa, Chika Taniguchi, Hitoshi Ichihashi
  • Patent number: 7662409
    Abstract: The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: February 16, 2010
    Assignee: Gel-Del Technologies, Inc.
    Inventor: David B. Masters
  • Patent number: 7619007
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: November 17, 2009
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Patent number: 7547452
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: June 16, 2009
    Assignees: Alkermes, Inc., Janssen Pharmaceutica, N.V
    Inventors: Thomas J. Atkins, Michael E. Rickey, Jean Mesens
  • Patent number: 7462626
    Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: December 9, 2008
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Eckard Weber, Michael Alexander Cowley
  • Patent number: 7449236
    Abstract: Embolic particles, as well as their methods of use and manufacture, are described.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: November 11, 2008
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Janel L. Lanphere, Ernest J. Pierre, Greg Kapoglis, Thomas V. Casey, II
  • Patent number: 7439269
    Abstract: An improved composition and method for moisturizing a nasal membrane are disclosed. The composition includes a viscous carrier and one or more moisturizing agents disposed with the carrier. The composition is applied to a portion of a nasal membrane using a spray, a swab applicator, or a similar application device.
    Type: Grant
    Filed: April 18, 2005
    Date of Patent: October 21, 2008
    Assignee: Matrixx Initiatives, Inc.
    Inventors: Tim Clarot, Charles Hensley
  • Patent number: 7423068
    Abstract: The present invention is directed to methods and compositions for use to control parasitic mites of honey bees, particularly Varroa mites. In one aspect, the invention is directed to control of parasitic mites of honey bees wherein the active ingredient is a miticidally effective amount of a selected ketone or 1-heptanol, ethyl butyrate, benzaldehyde, heptaldehyde, or d-limonene. In a second aspect, the invention is directed to control of parasitic mites of honey bees wherein the active ingredient is an effective attractant amount of 2-heptanone. The attracted mites are then trapped or otherwise removed from the locus of the bees. The present invention is also directed to methods and compositions which include 2-heptanone to control hive invading pests of honey bees.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: September 9, 2008
    Assignees: The United States of America as represented by the Secretary of Agriculture, Cerexagri, Inc.
    Inventors: Eric H. Erickson, Jr., Gloria DeGrandi-Hoffman, Christian G. Becker, Roy S. Whitson, Thomas A. Deeby
  • Patent number: 7381715
    Abstract: A solid surface material with an antimicrobial agent in a thermoset and/or thermoplastic resin matrix where the antimicrobial agent comprises a chitosan-metal complex.
    Type: Grant
    Filed: November 30, 2004
    Date of Patent: June 3, 2008
    Assignee: E.I. du Pont de Nemours and Company
    Inventor: Subramaniam Sabesan
  • Patent number: 7342048
    Abstract: A bioabsorbable release-sustaining pharmaceutical formulation using a biodegradable release-sustaining base material which can prevent an effective component drug from being released too rapidly just after administration of the formulation and then allow continued release of the drug for at least one month at a defined rate, is provided. For the biodegradable release-sustaining base material, a lactic acid-glycolic acid copolymer (PLGA) with an adjusted distribution in molecular weight is used.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: March 11, 2008
    Assignee: Nipro Corporation
    Inventors: Tatsuaki Miyaji, Makoto Sato, Tamaki Murayama, Yohei Hoashi, Hisae Saito, Takao Okada, Yukari Imamura, Yoshimichi Fujiyama
  • Patent number: 7314638
    Abstract: The present invention relates to a simple and effective method for preparing a tamsulosin HCl sustained-release tablet and a tamsulosin HCl sustained-release tablet produced thereby. The method comprises the steps of: dissolving tamsulosin HCl as an active ingredient in an organic solvent; dissolving the tamsulosin HCl solution in hydroxypropylmethylcellulose phthalate to prepare a binder solution; and kneading the binder solution with a hydroxypropylmethylcellulose phthalate/glyceryl dibehenate mixture as an excipient and allows tamsulosin HCl to be released at uniformly controlled amounts in a subtained-release manner in vivo by controlling drug release rate according to different pH environments in vivo, so that it shows improved bioavailability and minimized side effects.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: January 1, 2008
    Assignee: Kyungdong Pharm. Co., Ltd.
    Inventors: Byoung-Suk Lee, Ah-Ram Lee, Jong-Sik Park, Eun-Ju Kim, Hyung-Joon Gil
  • Patent number: 7270834
    Abstract: A pharmaceutical composition to be externally applied as a topical preparation for treating several diseases, the composition comprising dimethylsulfoxide (DMSO) and ozone. A method for obtaining the composition by ozonizing DMSO and a method for treating diseases by applying the composition are also provided.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: September 18, 2007
    Inventors: Haydee Alba Stenti, Claudia Pirillo, Jose Maria Pastoriza
  • Patent number: 7229642
    Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: June 12, 2007
    Assignee: Scolr, Inc.
    Inventors: A. Reza Fassihi, Thomas Dürig
  • Patent number: 7226607
    Abstract: Compositions for providing controlled-release of an active material comprise a dispersant and microcapsules containing the active material and a stabilizer. The compositions contain the dispersant and/or microcapsules at relatively low levels to avoid negatively impacting the surfaces treated with the compositions. The active material is preferably a perfume and the composition provides a controlled-release scent, along with controlling malodor when the compositions further comprise optional odor control agent. The stabilizer improves the stability of the microcapsule. Methods of providing a controlled-release of an active material on a surface comprise the step of contacting the surface with a composition comprising a dispersant and microcapsules containing an active material and a stabilizer.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: June 5, 2007
    Assignee: The Procter & Gamble Company
    Inventors: Hirotaka Uchiyama, Jonathan Robert Cetti, Mario Alonso, Christine Marie Readnour, Zaiyou Liu, Carl Eric Kaiser, Michele Denise Shirley, Daniel Scott Cobb
  • Patent number: 7223724
    Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: May 29, 2007
    Assignee: Human Genome Sciences, Inc.
    Inventors: Ralph Alderson, Robert Melder, Viktor Roschke, Steven M. Ruben, Craig A. Rosen
  • Patent number: 7144585
    Abstract: Provided is a cilostazol preparation which comprises incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent thereby to enhance the dispersibility and/or solubility. Further, provided is a process for improving absorbability of a slightly soluble drug such as cilostazol even at the lower portion of the digestive tract, wherein said drug is hard to be absorbed at the lower portion of the digestive tract when a conventional method is used. According to the present invention, cilostazol is absorbed enough even at the lower portion of the digestive tract to have an effect as thrombolytic drug, cerebral circulation improving drug or the like.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: December 5, 2006
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Tadashi Mukai, Yuso Tomohira, Masafumi Toda, Keigo Yamada, Yoshikazu Oka
  • Patent number: 7118761
    Abstract: Wound care devices having a topically applied silver-based antimicrobial finish are provided. The finish comprises at least one silver ion-containing compound and at least one binder compound. The finish may be applied to a target substrate, such as a fiber, fabric, film, foam, hydrogel, or hydrocolloid to provide a single layer antimicrobial wound care device. Alternatively, a silver-containing layer may be combined with one or more additional layers of target substrate to provide a composite antimicrobial wound care device. The device may also contain an odor-absorbing component capable of reducing or eliminating odors that are inherently associated with infectious wounds. Also provided is a method for making the wound care device and a composition of matter comprising the silver-based antimicrobial finish.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: October 10, 2006
    Inventors: T. Andrew Canada, Robert L. Schuette, Raymond C. Sturm, Kenneth M. Wiencek, Jason L. Kreider
  • Patent number: 7109166
    Abstract: This invention is directed to a sustained release composition comprised of Compound (A) having the formula or a pharmaceutically acceptable salt thereof, and a copolymer comprised of poly-(I)-lactic-glycolic-tartaric acid wherein the amino group of Compound (A) is ionically bound to a carboxyl group of the copolymer and wherein further the composition may be made into a sustained release pharmaceutical composition with pharmaceutically acceptable carrier(s).
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: September 19, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, SAS
    Inventor: Jacques-Pierre Moreau
  • Patent number: 7108865
    Abstract: A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: September 19, 2006
    Assignee: Pfizer Inc
    Inventors: William J. Curatolo, Hylar L. Friedman, Richard W. Korsmeyer, Steven R. LeMott
  • Patent number: 7087619
    Abstract: Urinary incontinence is alleviated in a mammal by administering to the mammal a urinary incontinence alleviating amount of dextromethorphan, dextrorphan, their mixtures and/or pharmaceutically acceptable salts, alone or in combination with a pharmacologically active agent such as an anticholinergic, sympathomimetic, tricyclic antidepressant, antispasmodic, direct-acting smooth muscle relaxant, estrogen, compound having estrogen-like activity, or any combination of the foregoing.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: August 8, 2006
    Assignee: Endo Pharmaceuticals, Inc.
    Inventor: Frank S. Caruso
  • Patent number: 7087249
    Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: August 8, 2006
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Robert Edward Burrell, Antony George Naylor, Peter Howard Moxham
  • Patent number: 7078060
    Abstract: Solutions and aerosols of metal-containing compounds are disclosed. Methods of preparing and using the solutions and aerosols, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: July 18, 2006
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Robert E. Burrell, John B. Wright, Kan Lam, Hua Qing Yin, Antony G. Naylor, Peter H. Moxham, Scott H. Gillis, Paul Schechter
  • Patent number: 7074432
    Abstract: The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: July 11, 2006
    Assignee: Alkermes Controlled Therapeutics, Inc.
    Inventors: James R. Dasch, M. Gary I. Riley
  • Patent number: 7056865
    Abstract: Improved cation exchange zeolite crystalline and zeolite-like plant bed structures are disclosed, preferably saturated with water-based extracts of particular plant/herb materials exhibiting plant growth acceleration properties and synergistically providing also nutrient, and sometimes anti-microbial and insect and fungus repellent properties, as well, and with the adaptability to present the structures in solid, gel and liquid form.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: June 6, 2006
    Assignee: Allor Foundation
    Inventors: Robert H. Rines, Lisa Toth, Suzi Rines Toth
  • Patent number: 7045496
    Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: May 16, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Ralph Alderson, Robert Melder, Viktor Roschke, Steven M. Ruben, Craig A. Rosen
  • Patent number: 7041317
    Abstract: A sustained-release formulation of 5-acetyl-4,6-dimethyl-2-[2-[4-(2-methoxyphenyl)piperazinyl]ethylamino]pyrimidine trihydrochloride coated with a release-controlling film comprising a water-insoluble polymer film having no hydrophilic group. The formulation of the present invention has such a release pattern that the drug release lasts for 20 hours or more, so that can be appropriately administered for treatment. Furthermore, the formulation itself is so stable that its release pattern does not change with pH and the formulation does not suffer from deterioration, coloration and the like with the lapse of time.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: May 9, 2006
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Noboru Sekiya, Yoshinori Ii, Masayuki Ishikawa, Hiroshi Azuma
  • Patent number: 7029701
    Abstract: The invention relates to pharmaceutical compositions comprising omeprazole and aspirin wherein the combination is useful for the treatment and prevention of cardiovascular events including heart attacks and platelet aggregation leading to a potential cardiac event. A variety of drug delivery systems may be utilized to deliver the combination of active ingredients. The preferred delivery system utilizes a tablet or capsule containing an inert sugar core particle that is coated with subparticles of a coated omeprazole wherein the coating contains omeprazole, a binder, a surface active agent and a basifying agent along with a filler. The aspirin may be combined with this formulation to coat the sugar sphere or it may be part of a separate coating composition that forms a multilayer system that is ultimately coated with an enteric coating and then formed into the tablet or capsule by conventional means.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: April 18, 2006
    Assignee: Andrx Pharmaceuticals, LLC
    Inventor: Chih-Ming Chen
  • Patent number: 7030162
    Abstract: The invention is directed to pharmaceutical compositions useful in the treatment of migraine. The compositions contain metoclopramide and one or more NSAIDs in unit dosage form. By selecting NSAIDs that are non-acidic or segregating the metoclopramide and NSAID, the storage life of the compositions has been increased. Also disclosed are coordinated dosage forms for the sequential release of drugs. The invention encompasses methods of treating migraine using any of these dosage forms.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: April 18, 2006
    Assignee: POZEN Inc.
    Inventors: John R. Plachetka, Zakauddin T. Chowhan
  • Patent number: 7025989
    Abstract: An antibiotic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: April 11, 2006
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 7014871
    Abstract: An iodine preparation composition suitable for use on wounds comprising an iodide source, an oxidant and a buffer characterized in that the iodide is held separately from the oxidant until the point of use, and that the buffer is capable of maintaining the pH of the composition at between pH 45 and pH 6 so that iodine is generated at a physiologically acceptable dose rate.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: March 21, 2006
    Inventors: Dave Parsons, Elizabeth Jacques, Philip Bowler
  • Patent number: 7011854
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: March 14, 2006
    Assignee: Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda
    Inventors: Werner Haas, Carlos Romao, Beatriz Roya, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 7008647
    Abstract: The invention relates to the use of one or more antimicrobial metals selected from silver, gold, platinum, and palladium but most preferably silver, preferably formed with atomic disorder, and preferably in a nanocrystalline form, for the treatment of a acne. The nanocrystalline antimicrobial metal of choice may be used in the form of a nanocrystalline coating of one or more antimicrobial metals, a nanocrystalline powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: March 7, 2006
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Robert Edward Burrell, Hua Qing Yin
  • Patent number: RE41279
    Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: April 27, 2010
    Assignee: Ecolab Inc.
    Inventors: David D. McSherry, Francis L. Richter